Get started
Author

Santosh Kumar Pandey

Observed names: S Pandey, Santosh Pandey, Santosh kumar Pandey
Observed institution: Suven Life Sciences (India)
ORCID: 0000-0003-1753-0051
Observed ORCID: 0000-0003-1753-0051
OpenAlex ID: A5101551569
Determining the effect of storage conditions on prothrombin time, activated partial thromboplastin time and fibrinogen concentration in rat plasma samples
2015 · Vinod Kumar Goyal, Somesh Kakade, et al. · Laboratory Animals · 21
PDF
Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
2022 · Ramakrishna Nirogi, Pradeep Jayarajan, et al. · International Journal of Geriatric Psychiatry · 17
PDF
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects
2018 · Ramakrishna Nirogi, Koteshwara Mudigonda, et al. · Clinical Drug Investigation · 11
Evaluation of clinical chemistry analytes from a single mouse using diluted plasma: effective way to reduce the number of animals in toxicity studies
2015 · Vinod Kumar Goyal, Santosh Kumar Pandey, et al. · Laboratory Animals · 11
PDF
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
2024 · Ramakrishna Nirogi, Anil Shinde, et al. · Sleep Medicine · 10
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
2020 · Ramakrishna Nirogi, Koteshwara Mudigonda, et al. · Clinical Drug Investigation · 9
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization
2022 · Ramakrishna Nirogi, Renny Abraham, et al. · Psychopharmacology · 8
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
2022 · Ramakrishna Nirogi, Vinod Kumar Goyal, et al. · Neurology and Therapy · 7
PDF
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
2022 · Ramakrishna Nirogi, Vijay Benade, et al. · Clinical Drug Investigation · 5
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects
2021 · Ramakrishna Nirogi, Gopinadh Bhyrapuneni, et al. · Clinical Drug Investigation · 5
Short-term toxicity study of 1-aminobenzotraizole, a CYP inhibitor, in Wistar rats
2020 · Santosh Kumar Pandey, Harish Nakka, et al. · Drug and Chemical Toxicology · 4
0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates
2019 · Ramakrishna Nirogi, Gopinadh Bhyrapuneni, et al. · SLEEP · 4
P3‐016: SUVN‐D4010, A Potent and Selective 5‐HT4 Receptor Partial Agonist: Safety, Tolerability and Pharmacokinetics in Humans
2016 · Pradeep Jayarajan, Gopinadh Bhyrapuneni, et al. · Alzheimer s & Dementia · 4
PDF
P1‐310: Suvn‐g3031, an h3 receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models
2015 · Vijay S. Benade, Saivishal Daripelli, et al. · Alzheimer s & Dementia · 4
Masupirdine (SUVN-502): An Update on the Phase-3 Clinical Development Program Targeting Agitation in Patients with Dementia of Alzheimer’s Type (P1-3.020)
2025 · Ramakrishna Nirogi, Jyothsna Ravula, et al. · Neurology · 3
0120 SUVN-G3031, a Novel, Potent and Selective Histamine H3 Receptor Inverse Agonist for the Treatment of Narcolepsy: Preclinical Characterization
2019 · Gopinadh Bhayrapuneni, Venkatesh Kamuju, et al. · SLEEP · 3
P2‐026: SUVN‐G3031, a Potent and Selective H3 Receptor Inverse Agonist: Safety, Tolerability and Pharmacokinetics in Humans
2016 · Gopinadh Bhyrapuneni, Koteshwara Mudigonda, et al. · Alzheimer s & Dementia · 3
PDF
P1‐397: Suvn‐g3031: a Novel and Potent Histamine H3 Receptor Antagonist for Potential Treatment of Cognitive Deficits
2014 · Medapati Rajesh Babu, Nageswararao Muddana, et al. · Alzheimer s & Dementia · 3
PDF
P1‐398: Suvn‐d4010: Novel 5‐ht4 Receptor Partial Agonist for the Treatment of Alzheimer's Disease
2014 · Nageswararao Muddana, Ramkumar Subramanian, et al. · Alzheimer s & Dementia · 3
PDF
P3‐296: Safety, tolerability, and pharmacokinetics of a potent and selective 5‐ht6 receptor antagonist, SUVN‐502, following multiple ascending doses in healthy elderly subjects, and effect of gender and food on single‐dose pharmacokinetics
2015 · Ramakrishna Nirogi, Koteshwara Mudigonda, et al. · Alzheimer s & Dementia · 2
Update on the Development of SUVN‐I6107: A True Positive Allosteric Modulator of the Muscarinic M1 Acetylcholine Receptor for the Treatment of Dementia
2025 · Vijay Benade, Anil Shinde, et al. · Alzheimer s & Dementia · 1
Samelisant (SUVN-G3031): Positive Results from Phase-2 Proof-of-concept, Double-blind, Placebo-controlled Study in Patients with Narcolepsy and an Update on Further Clinical Development (S6.004)
2025 · Ramakrishna Nirogi, Jyothsna Ravula, et al. · Neurology · 1
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects
2023 · Ramakrishna Nirogi, Jyothsna Ravula, et al. · Cancer Chemotherapy and Pharmacology · 1
0051 Samelisant, a H3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease
2023 · Ramakrishna Nirogi, Vijay Benade, et al. · SLEEP · 1
PDF
004 Samelisant (SUVN-G3031), Differentiating features over current treatments of narcolepsy
2021 · Anil Shinde, Ramkumar Subramanian, et al. · SLEEP · 1
Works count: 46
Citation count: 145
H-index: 7
I10-index: 5
Year
Topic
Type